Progyny (NASDAQ:PGNY) Director Cheryl Scott Sells 7,439 Shares

Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total value of $196,315.21. Following the completion of the sale, the director directly owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. This trade represents a 27.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Progyny Price Performance

Progyny stock opened at $24.99 on Thursday. The company’s 50 day simple moving average is $20.27 and its 200 day simple moving average is $22.26. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 1.34 and a beta of 1.03.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.26 by $0.24. The firm had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business’s quarterly revenue was down 26.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, analysts predict that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Progyny announced that its Board of Directors has initiated a stock repurchase program on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PGNY shares. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Canaccord Genuity Group raised Progyny from a “hold” rating to a “buy” rating and boosted their price target for the stock from $19.00 to $30.00 in a research report on Tuesday, May 19th. KeyCorp dropped their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Bank of America raised their price objective on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Truist Financial boosted their target price on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PGNY. Principal Financial Group Inc. grew its position in shares of Progyny by 57.1% in the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after purchasing an additional 256,078 shares during the last quarter. Intech Investment Management LLC lifted its holdings in Progyny by 336.0% during the 3rd quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock worth $3,655,000 after purchasing an additional 130,885 shares during the last quarter. Vanguard Group Inc. boosted its stake in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares during the period. Algert Global LLC boosted its stake in Progyny by 35.1% in the 3rd quarter. Algert Global LLC now owns 595,805 shares of the company’s stock valued at $12,822,000 after purchasing an additional 154,930 shares during the period. Finally, Barclays PLC grew its holdings in Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after buying an additional 696,447 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.